PARP1 and ovarian carcinoma: We consider this value intermediate compared to other IC50 concentrations for BRCA1/2-mutated ovarian cancer cell lines treated with the PARP inhibitor rucaparib (chemically similar to AG-14361) as reported in the Sanger Institute database, which range from 9.8 μM - 315 μM with a medium IC50 of 31.5 μM [73].